郑清月,闫春良,赵秋红

• 1:北京航天总医院呼吸内科

摘要(Abstract)：

目的评价盐酸埃克替尼一线常规剂量治疗肺腺癌进展后盐酸埃克替尼加量治疗的疗效及安全性。方法收集22例ⅢB或IV期肺腺癌患者,经一线埃克替尼常规剂量(125 mg口服3次/d)治疗耐药后,给予盐酸埃克替尼加量治疗(150～450 mg口服3次/d),进行回顾性分析,评估埃克替尼加量疗效及安全性。结果 22例晚期肺腺癌患者中,完全缓解0例(0%),部分缓解7例(31.8%),疾病稳定9例(40.9%),疾病进展6例(27.3%),客观缓解率为31.8%,疾病控制率为72.7%,中位无进展生存期为6个月(95%CI:3.702～8.298个月),中位总生存期为11个月(95%CI:7.260～14.740个月)。埃克替尼加量治疗常见的不良反应为皮疹、食欲下降及腹泻,均为1～2级。结论对于一线盐酸埃克替尼常规剂量治疗耐药的晚期肺腺癌患者,盐酸埃克替尼加量治疗可作为二线选择方案。盐酸埃克替尼加量治疗安全性较高。

关键词(KeyWords)： 肺肿瘤/药物疗法;腺癌/药物疗法;喹唑啉类/治疗应用;喹唑啉类/投药和剂量;冠醚类/治疗应用;冠醚类/投药和剂量;治疗结果;安全;回顾性研究

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 郑清月,闫春良,赵秋红

DOI: 10.13267/j.cnki.syzlzz.2020.03.008

参考文献(References)：

• [1] Planchard D, Popat S, Kerr K,et al. Metastatic nonsmall cell lung cancer:ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol,2018, 29(4):192-237.
• [2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
• [3]张萍，武晓楠，聂鑫，等.晚期肺腺癌EGFR基因突变及临床特征分析[J].实用肿瘤杂志, 2018,33(2):150-153.
• [4] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology-non-small cell lung cancer(2019 version 2)[EB/OL].(2018-11-21)[2019-2-10].http://www.nccn.org.
• [5] Xu JP,Liu XY,Yang S,et al. Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure:a retrospective study[J]. Oncotargets Ther, 2017,(10):4989-4995.
• [6] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J]. Eur J Cancer, 2009,45(2):228-247.
• [7] Zago G, Muller M, van den Heuvel M, et al. New targeted treatments for non-small-cell lung cancer-role of nivolumab[J]. Biologics, 2016,10:103-117.
• [8]石远凯,孙燕,丁翠敏,等.中国埃克替尼治疗非小细胞肺癌专家共识[J].中国肺癌杂志, 2016,19(7):489-493.
• [9] Deng QF, Xie BX, Wu LL, et al. Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients[J]. Heliyon, 2018, 4(12):e01031.
• [10] Wang HP, Zhang L, Si XY, et al. Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy[J]. Oncotargets Ther,2018,11:7513-7519.
• [11]郁佳，吴凤英，张世佳，等.EGFR突变晚期NSCLC患者MDT诊治报道[J].实用肿瘤杂志, 2017,32(4):291-295.
• [12] Liu J, Wu LH, Wu GL, et al. A phaseⅠstudy of the safety and pharmacokinetics of higher-dose icotinib in patients with advanced non-small cell lung cancer[J]. Oncologist,2016, 21(11):1294-1295.
• [13] Ni J, Zhang L. Evaluation of three small molecular drugs for targeted therapy to treat non-small cell lung cancer[J].Chin Med J, 2016,129(3):332-340.
• [14]吕丽英，王留兴.盐酸埃克替尼加量治疗晚期肺腺癌的临床研究[D].郑州：郑州大学第一附属医院，2018.
• [15] Shi YK, Wang L, Han BH, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma(CONVINCE):a phase 3, open-label, randomized study[J]. Ann Oncol, 2017, 10(28):2443-2450.